INTRODUCTION {#s1}
============

The "liquid biopsy" is becoming an increasingly important tool in precision oncology\'s goal of transforming cancer care, quickly moving from the research setting into the clinic ([@MCS003269MARC31]). Overwhelmingly, however, the power of this technology has been focused on issues related to advanced disease in already diagnosed patients under active treatment. For example, and following initial treatment, liquid biopsies are used to detect the presence of minimal residual disease, predict disease recurrence, assess the emergence of drug resistance, and provide guidance for tailored salvage treatment ([@MCS003269MARC12]; [@MCS003269MARC25]; [@MCS003269MARC29]; [@MCS003269MARC19]). By marked contrast, advances in early cancer detection remain both limited and limited in degrees of success ([@MCS003269MARC26]). One of the key constraints cited is the implicit rarity of finding circulating tumor DNA (ctDNA) molecules and circulating tumor cells (CTCs) when a tumor is small and still in an early stage ([@MCS003269MARC28]; [@MCS003269MARC4]). Beyond this, identifying ctDNA or CTCs by liquid biopsy provides no definitive information on tumor type or origin.

Although analytic techniques for early detection will require improvements for overcoming these intrinsic barriers to blood sampling, a parallel possibility exists for developing alternative sampling strategies ([@MCS003269MARC31]). We and others have recently explored the use of a uterine lavage to detect endometrial and ovarian cancers ([@MCS003269MARC17]; [@MCS003269MARC24]). Indeed, sequencing cellular and cell-free DNA (cfDNA) isolated from uterine lavage fluid in a prospective study allowed detection of 100% of all endometrial cancers, including even microscopic stage IA cancers ([@MCS003269MARC24]). The ability to detect microscopic-sized cancers by this targeted sampling approach immediately suggested the potential for early cancer detection and a broader-based approach toward endometrial cancer screening and prevention.

Endometrial cancer is the most common gynecologic malignancy in industrialized countries, and both its incidence, most likely linked to the rise in obesity, and associated mortality are increasing ([@MCS003269MARC20]). The genomic landscape of primary endometrial cancers and their metastases have been detailed ([@MCS003269MARC7]; [@MCS003269MARC13]) and morphologically defined premalignant tissue lesions, each with different attributable risks of progression to carcinoma, have been defined ([@MCS003269MARC3]). Despite these well-recognized genetic and pathological associations, there are no screening tests.

Here, we present proof of principle for early endometrial cancer detection using a targeted liquid biopsy technique. This illustrative case provides the first demonstration that future, tumor-specific mutations can be identified in an asymptomatic individual without clinical or pathologic evidence of cancer. In this individual, mutations were identified nearly 1 yr before symptoms developed, and a single, microscopic focus of cancer was eventually diagnosed.

RESULTS {#s2}
=======

We report the case of an asymptomatic 67-yr-old female with a BMI of \>34 who had initially been referred to gynecologic oncology for follow-up evaluation of an abnormal endometrial stripe detected as an incidental finding during a pelvic sonography for kidney stone evaluation. Family history was negative for any evidence of breast, pancreatic, ovarian, or endometrial cancers. On examination, the patient was found to have a stenotic cervix that prevented an in-office endometrial biopsy. She therefore underwent hysteroscopy and dilation and curettage in the operating room under anesthesia. The patient was enrolled in our study to sequence cellular DNA and cfDNA isolated from uterine lavage fluid collected during hysteroscopy as a potential cancer diagnostic ([@MCS003269MARC24]). Ten milliliters of saline fluid hysteroscopy lavage was collected for molecular analysis and DNA was sequenced at ultra-high coverage (\>7000×) using a 12-gene, custom endometrial cancer typing panel, as previously described ([@MCS003269MARC24]).

Intraoperative findings revealed no gross evidence of malignancy in the uterine cavity that was scraped aggressively. Histopathologic analysis revealed benign endometrium with no evidence of hyperplasia or cancer. In contrast, molecular analysis of the lavage cell pellet identified a total of five driver mutations in four genes. The gene mutations and their allele frequencies (AFs) and sequencing coverage were *PTEN* R130G (1.3%/107 reads) and S338fs (1.1%/349 reads); *PIK3CA* N345I (4.9%/379 reads); *FBXW7* R505C (5.0%/467 reads); and *FGFR2* S252W (5.1%/355 reads).

Comparison of these mutations against The Cancer Genome Atlas (TCGA) endometrial cancer data set, using the cBioPortal tool ([@MCS003269MARC11]), revealed each mutation to be previously associated with this cancer. Strikingly, the *PTEN* R130 site is mutated in nearly 48% of all tumors. In order, the comparative frequencies of the other uterine lavage-detected mutations in the TCGA data set were *FGFR2* S252W, 7.4%; *FBXW7* R505C, 5.0%; *PIK3CA-N345I*, 4.1%, and *PTEN* S338fs, 0.8%.

Ten months later, the patient returned with a chief complaint of postmenopausal bleeding. In-office biopsy revealed complex hyperplasia with atypia, a known preneoplastic tissue lesion, suspicious for low-grade endometrioid adenocarcinoma. The patient was brought to the OR for total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic sentinel lymph node mapping, and resection. Pathology revealed a single microscopic focus of endometrioid endometrial adenocarcinoma without any evidence of myometrial invasion ([Fig. 1](#MCS003269MARF1){ref-type="fig"}A).

![(*A*) A section of the H&E-stained biopsy containing normal tissue and tumor is shown with a superimposed and magnified image highlighting the tumor from which laser-capture microdissection (LCM) was performed. Diagnosis revealed the single focal grade 1 endometrioid endometrial adenocarcinoma, stage IA, without evidence of myometrial invasion. (*B*) An overview of the mutational profile of the six patients, including the index case, possessing *PTEN* 130 mutations. The sum of all mutations---driver, potential driver, and unknown significance---is shown for each patient.](MCS003269Mar_F1){#MCS003269MARF1}

Laser-capture microdissection (LCM) was used to isolate tumor tissue for molecular analysis. DNA was extracted and sequenced. The two oncogenic somatic *PTEN* mutations, R130G and Ser338fs, first identified 10 mo earlier in the uterine lavage cell pellet, were present in the tumor at AFs now \>10%. We then calculated the probability that the shared *PTEN* mutations could occur by chance alone. To estimate this likelihood, we made the assumption that all positions interrogated by our 12-gene sequencing panel could be mutated with equal probability. Under this assumption, it is highly unlikely that the two identical *PTEN* mutations identified in two samples---preclinical lavage and LCM---would occur by chance alone (*P* \< 3 × 10^−7^).

DISCUSSION {#s3}
==========

Using an integrated liquid biopsy--based and cancer-targeted sampling approach, we have established a benchmark for earliest endometrial cancer detection. Previous studies by others had demonstrated that occult cancers can be detected through blood-based sampling. These studies included incidental detection of various cancers in women following unexplained chromosomal aneuploidies identified during noninvasive prenatal testing ([@MCS003269MARC1]; [@MCS003269MARC5]; [@MCS003269MARC10]) and nasopharyngeal cancer through the targeted tracking of Epstein--Barr virus (EBV) DNA in an endemic but asymptomatic population ([@MCS003269MARC8]). Meanwhile, nearly 25 years ago, a retrospective study of cytology samples from lung cancer patients revealed that cancer cells can be present in the sputum prior to detection by chest X-ray diagnosis ([@MCS003269MARC16]). Taken together, we believe all these results establish both proof of principle for cancer screening by liquid biopsy and the paradigm for collection and analysis of relevantly targeted samples beyond blood.

For more than 70 years, it has been appreciated that endometrial and ovarian cancers and their precursors exfoliate cells into the uterine cavity ([@MCS003269MARC30]), and for almost as long, attempts have focused on obtaining these cancerous/precancerous cells for diagnostic purposes ([@MCS003269MARC18]). Nonetheless, screening for these cancers is an unmet clinical need. In our studies, we coupled the advances in next-generation sequencing (NGS) technologies and bioinformatics to an almost abandoned technique first introduced 60 years ago, concurrent with the Papanicolaou (Pap) test for detecting cervical cancer, the uterine lavage ([@MCS003269MARC21]). In the future, the uterine lavage and molecular analysis could be performed in-office. It would avoid the time and costs associated with uterine sonography and the costs, pain/discomfort, risks, time, and need for anesthesia associated with an in--operating room hysteroscopy. Beyond this, a simpler, more sensitive, and cost-effective in office procedure for screening for these cancers in all women including those at increased risk because of age, BMI, or inherited predisposition could have major effects on mortality and morbidity and could also remove barriers that have kept minorities and women of lower socioeconomic status from receiving equal care and the opportunity for improved outcomes ([@MCS003269MARC9]).

Although the potential paradigm shift for early cancer detection is obvious, the clinical dilemma introduced on molecular diagnosis of a precancer is also illustrated by this case. The driver mutations identified in the patient\'s uterine lavage were known to be bona fide signatures of endometrial cancer as revealed by comparison with TCGA data set. The presence of these mutations in cells isolated from the lavage would be expected to impart not only a possible proliferative advantage but also some degree of cancer risk notwithstanding the fact that the patient was asymptomatic and without evidence of premalignant changes on biopsy. However, no estimate of the likelihood or timing of future cancer onset could be made. Specifically, two independent studies have now demonstrated a high prevalence of cancer driver mutations in endometrial cells from women in the absence of endometrial cancer or morphologically recognized premalignant lesions ([@MCS003269MARC24]; [@MCS003269MARC2]). *PTEN* mutations have long been recognized as being relatively common findings in histologically normal premenopausal endometrium isolated during the proliferative phase of the menstrual cycle (e.g., see [@MCS003269MARC22], [@MCS003269MARC23]). In addition, an ever-increasing list of studies have demonstrated an accumulation of age-related, genetic driver mutations in blood and tissues in individuals with benign conditions and no evidence of cancer ([@MCS003269MARC15]; [@MCS003269MARC31]). Taken together, these findings suggest that what we have defined as cancer "driver mutations" may in actuality be necessary but not sufficient for cancer development ([@MCS003269MARC6]).

Given that the two *PTEN* mutations identified in the patient\'s lavage were tumor-specific (i.e., present in the original tumor), we therefore interrogated our original study of 102 women to identify other women who also possessed these specific *PTEN* mutations in their uterine lavage ([@MCS003269MARC24]). A total of five other cases with *PTEN* mutations at the R130 site were identified (patients 2--6; see [Tables 1](#MCS003269MARTB1){ref-type="table"} and [2](#MCS003269MARTB2){ref-type="table"}). These five patients, in order, were previously noted as PT468, PT395, PT476, PT459, and PT513). A histogram of the number and classifications of all mutations, including the *PTEN* R130 mutation, identified in the lavages from all the patients is shown in [Figure 1](#MCS003269MARF1){ref-type="fig"}B.

###### 

Patients detected with mutations at the *PTEN* R130 site

  Patient                                                                                                   Age   BMI   Chief complaint at presentation                                                                          Final pathology                                                                                                                              Gene---*PTEN*          *PTEN* detection status in lavage   Follow-up period                                     
  --------------------------------------------------------------------------------------------------------- ----- ----- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ----------------------------------- ------------------ ----------- ---------- ---------- -------
  1                                                                                                         67    34    Pelvic pain; abnormal uterine sonogram detected as an incidental finding during workup for renal stone   *Initial presentation*: benign endometrium with no evidence of hyperplasia or cancer                                                         10:87933147-87933147   c.388C\>G                           R130G              121909224   +(1.3%)    \-         14 mo
  *On return*: single microscopic focus of FIGO grade 1, stage IA endometrioid endometrial adenocarcinoma                                                                                                                                                                                                                                                                                                                                                                                     
  2                                                                                                         67    39    Postmenopausal bleeding; thickened endometrium detected on sonogram                                      FIGO grade 3, stage IA endometrioid endometrial adenocarcinoma; mixed type histology                                                         10:87933148-87933148   c.389G\>A                           R130Q              121909229   +(21.9%)   +(38.8%)   NA
  3                                                                                                         51    22    Postmenopausal bleeding                                                                                  Proliferative endometrium with polypoid fragments and glandular/stromal breakdown                                                            10:87933147-87933147   c.388C\>G                           R130G              121909224   +(2.4%)    \-         30 mo
  4                                                                                                         37    34    Dysmenorrhea; endometriosis                                                                              Proliferative endometrium; bilateral benign endometriotic cysts; pelvic peritoneum and uterosacral ligament biopsies showing endometriosis   10:87933148-87933148   c.389G\>A                           R130Q              121909229   +(1.3%)    \-         26 mo
  5                                                                                                         47    23    Postmenopausal bleeding; endometriosis                                                                   Benign endometrium, superficial adenomyosis, early secretory endometrium                                                                     10:87933147-87933147   c.388C\>G                           R130G              121909224   +(1.6%)    \-         26 mo
  6                                                                                                         41    19    Abnormal uterine bleeding; polyp on sonogram                                                             Polyp with proliferative glands and focal simple hyperplasia without atypia, proliferative endometrium                                       10:87933147-87933147   c.388C\>T                           R130\*             121909224   \-         +(1.7%)    26 mo

BMI, body mass index; dbSNP, Single Nucleotide Polymorphism database; AF, allele frequency; NA, not available; FIGO, International Federation of Gynecology and Obstetrics.

###### 

*PTEN* R130 site variant information

  Gene                   Chr:pos                HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect   dbSNP          Genotype       ClinVar ID
  ---------------------- ---------------------- -------------------- ------------------------ -------------- ------------------ -------------- -------------- ------------
  *PTEN*                 10:87933147-87933147   c.388C\>G            R130G                    Missense       Pathogenic         121909224      Heterozygous   375958
  10:87933148-87933148   c.389G\>A              R130Q                Missense                 Pathogenic     121909229          Heterozygous   7829           
  10:87933147-87933147   c.388C\>T              R130\*               Nonsense                 Pathogenic     121909224          Heterozygous   7819           

HGVS, Human Genome Variation Society; dbSNP, Single Nucleotide Polymorphism database.

The eldest of the cases (patient 2) was a 67-yr-old female with a BMI \> 38 who was originally evaluated for postmenopausal bleeding and thickened endometrium with endometrial nodules detected on sonography. A stage IA mixed histology cancer, one component being high-grade serous adenocarcinoma and the other being grade 3 endometrioid adenocarcinoma, was identified at the time of hysteroscopy and surgery. Ten driver gene mutations in five genes (*ARID1A*, *RB1*, *PIK3R1*, *PIK3CA*, and *PTEN*) were detected in her lavage fluid, including a *PTEN* R130Q mutation in both the cell pellet (AF 22%) and cfDNA (AF 39%) ([@MCS003269MARC24]). Tumor DNA was isolated, and the *PTEN* R130Q mutation was orthogonally confirmed by Sanger sequencing (AF 32%).

The four other cases (patients 3--6) were all younger than the two with endometrial cancer by \>20 yr (age range: 37--51) and as a group had a lower average BMI (average: 25; range: 19--34). Three of the women were originally evaluated for abnormal uterine bleeding and the fourth for dysmenorrhea. Two of the women also had endometriosis. *PTEN* uterine lavage mutation status is shown in [Tables 1](#MCS003269MARTB1){ref-type="table"} and [2](#MCS003269MARTB2){ref-type="table"}. At the time of their surgical exploration, none of these women had morphologic evidence of precancer lesions or cancer. Unlike patients 1 and 2 who developed cancer, none of these four women have demonstrated evidence of cancer symptoms during the \>2 yr follow-up since their original hysteroscopy procedure and lavage.

At the very outset of the patient care spectrum, precision oncology offers the holy grail---early cancer detection with the possibility of prevention. Our case report highlights the fact that although the opportunity exists, there remains an unexpected but surmountable bottleneck in immediately translating these findings to patients. As recently highlighted by a blue ribbon panel convened to guide the NCI\'s future U.S. cancer research priorities, "\[t\]he rate-limiting step in developing and implementing precision-based prevention approaches has been our limited understanding of precancer biology, which stands in contrast with the extensive knowledge of advanced disease" ([@MCS003269MARC14]). We have no guidance in understanding the order in which and at what point, if ever, somatic mutations identified prior to the development of morphologically defined preneoplastic lesions result in cancer.

This knowledge gap has engendered a call for a concerted effort to create a Pre-Cancer Genome Atlas (PCGA) ([@MCS003269MARC14]; [@MCS003269MARC27]). Moving beyond the previously successful goal of TCGA in cataloging the genomic landscape of advanced disease, the future goal would be to integrate the multiomics landscape and order the sequence of events and immunologic features that result in cancer. By way of a marathon analogy, interviewing only the elite runners as they cross the finish line (TCGA) reveals nothing about the larger total field of runners, those who dropped out and why, and whether we can reasonably predict if the remaining runners will complete or abandon the course (PCGA).

In conclusion, the sequencing technology and targeted sample collection methods are now available to facilitate detection of microscopic-sized tumors and even cells containing tumor-specific mutations before morphologically recognized tissue changes are diagnosed. In general, early detection would have marked benefits on patient survival, quality of life, and health-care costs. We now need to establish the road map detailing the steps leading from precancer to malignancy, and the converse, preventing precancer from developing into malignancy, so that we can make the giant leap from laboratory to clinically relevant prevention and detection of earliest cancers.

METHODS {#s4}
=======

Patient Enrollment {#s4a}
------------------

All samples used in this study were collected in accordance with the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (GCO\# 10--1166) at the time of the original diagnostic procedure as we have previously described, and all patients provided written consent ([@MCS003269MARC24]). All experimental protocols were approved by the Icahn School of Medicine at Mount Sinai in accordance with our research protocol (GCO\# 10--1166). All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from each patient.

Uterine Lavage and DNA Isolation {#s4b}
--------------------------------

Uterine lavage specimens were collected in the operating room at the time of a patient\'s hysteroscopy, as we have previously described ([@MCS003269MARC24]). Immediately upon entering the uterine cavity with the hysteroscope, the initial 20--30 ml of saline fluid, used to dilate the uterus, was then collected using a 40-ml specimen trap device (Medline Mucus Specimen Trap 40cc, No. DYND44140, Venture Respiratory Inc) attached to suction. Following the lavage collection, the patient underwent the remainder of their procedure as per their surgeon\'s discretion while the lavage samples in the specimen trap device were placed on ice and taken to the laboratory and processed within 1 h of collection.

In the laboratory, the lavage specimens were transferred to 50-ml centrifuge tubes and centrifuged. The acellular supernatant was separated from the cell pellet using a pipette and recentrifuged to remove any remaining cellular material and debris. This fraction was then collected and stored at −80°C until final DNA extraction. The cell pellet was washed with red blood cell lysis solution (5 Prime, No. 2301310), resuspending by gentle pipetting, incubating at room temperature, and then centrifuging in a tabletop centrifuge. The RBC lysis supernatant was then discarded, leaving behind the cell pellet. This was repeated until the cell pellet was cleared of visible red cell contamination. The cell pellet was stored at −80°C until DNA isolation was performed.

cfDNA was first concentrated from the acellular portion using a centrifugal filter (Amicon Ultra-15 30 kiloDalton Filter Units, EMD Millipore, No. UFC903096) into smaller volumes. The concentrated cfDNA was then extracted (Circulating Nucleic Acid Kit, QIAGEN). Cellular DNA was extracted from the cell pellets (ArchivePure DNA Kit, 5 Prime) using a modified protocol to account for low cell density. Germline DNA was isolated from peripheral blood samples collected from each patient at the time of their hysteroscopy (ArchivePure DNA Kit, 5 Prime). DNA concentrations of all fractions were determined by QuBit fluorometry (Thermo-Fischer Scientific).

For LCM, paraffin-embedded tumor samples were cut into two 10 µm thickness sections and subjected to microdissection (PixCell IIe Laser Capture Microdissection System microscope, Arcturus). Genomic DNA was extracted from the isolated caps by following the protocol in the Applied Biosystems PicoPure DNA Extraction Kit.

Library Preparation and Next-Generation Sequencing {#s4c}
--------------------------------------------------

As we have previously described these methods in great detail ([@MCS003269MARC24]), we describe them briefly herein. For all the patients described in the study, a set of sample trios from germline PBMC DNA and lavage cellular and acellular were sequenced to an average of 5000× coverage using a targeted amplicon panel (Swift Biosciences). Samples were either sequenced using the Accel-Amplicon 56G Oncology Panel (Swift Biosciences) or a specifically designed smaller custom endometrial tumor amplicon panel. The 12 genes in this smaller panel were *PTEN*, *PIK3CA*, *TP53*, *CTNNB1*, *KRAS*, *FGFR2*, *FBXW7*, *RB1*, *ATM*, *APC*, *ARID1A*, and *PIK3R1*. The genomic target regions were designed to cover both hotspot loci and contiguous full-coding exons, including the full exonic coverage of TP53 (see Supplemental Table 1 in [@MCS003269MARC24] for a complete listing of all genomic loci covered).

Resulting targeted NGS libraries were sequenced on an Illumina MiSeq using v2 chemistry. Somatic variant calling was performed using MuTect, VarScan, and LoFreq after following GATK Best Practices. A target of 5000× coverage and 10-ng inputs enabled the lower limit of detection to be set to the 1% fraction.
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The variants described in this paper have been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000803739 and SCV000808062.
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